US Stock Insider Trading | Cytokinetics disclosed two insider trading transactions on February 5

K-LinePoet · 2026-02-28T06:36:48+00:00

Cytokinetics disclosed on February 5, 2026, that executive Callos Andrew engaged in insider trading, buying 15,000 shares and selling the same amount. The company focuses on developing novel small molecule therapies aimed at providing potential treatments for major diseases.

K-LinePoet

2026-02-28 06:36:48

Abstract generation in progress

On February 5, 2026, Cytokinetics (CYTK) disclosed two insider trading transactions. Executive Callos Andrew purchased 15,000 shares.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 5, 2026	Executive	Callos Andrew	February 5, 2026	Buy	15,000	23.26	348,900
February 5, 2026	Executive	Callos Andrew	February 5, 2026	Sell	15,000	61.93	929,000
February 2, 2026	Executive	Callos Andrew	February 2, 2026	Sell	886	62.10	55,000
February 2, 2026	Executive	Callos Andrew	February 2, 2026	Buy	886	37.63	33,300
January 20, 2026	Director	Daly James M	January 15, 2026	Buy	197	63.44	12,500
January 16, 2026	Director	Harrington Robert Arthur, HENDERSON JOHN T, Kaye Edward M. MD, WIERENGA WENDELL, Wysenski Nancy	January 15, 2026	Buy	924	63.44	58,600
January 5, 2026	Executive	Callos Andrew	January 5, 2026	Sell	15,000	60.28	904,200
January 5, 2026	Executive	Callos Andrew	January 5, 2026	Buy	15,000	23.26	348,900
January 2, 2026	Executive	Callos Andrew	January 2, 2026	Sell	885	63.16	55,900
January 2, 2026	Executive	Callos Andrew	January 2, 2026	Sell	913	62.09	56,700

【Company Profile】

Cytokinetics, Incorporated was founded on August 5, 1997, and is incorporated under Delaware law. It is a clinical-stage biopharmaceutical company primarily focused on discovering and developing novel small molecule therapies that modulate muscle function, aiming to provide potential treatments for serious diseases and medical conditions. The company is currently in the development phase, emphasizing research, drug screening technologies, and financing.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.